Compare EOS & NVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EOS | NVAX |
|---|---|---|
| Founded | 2005 | 1987 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.1B |
| IPO Year | N/A | 1995 |
| Metric | EOS | NVAX |
|---|---|---|
| Price | $23.29 | $7.28 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $9.75 |
| AVG Volume (30 Days) | 84.1K | ★ 3.3M |
| Earning Date | 01-01-0001 | 02-26-2026 |
| Dividend Yield | ★ 6.80% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 2.07 |
| Revenue | N/A | ★ $1,064,651,000.00 |
| Revenue This Year | N/A | $58.91 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $3.51 |
| Revenue Growth | N/A | ★ 20.27 |
| 52 Week Low | $15.62 | $5.01 |
| 52 Week High | $20.63 | $10.65 |
| Indicator | EOS | NVAX |
|---|---|---|
| Relative Strength Index (RSI) | 56.66 | 57.22 |
| Support Level | $23.07 | $6.60 |
| Resistance Level | $23.38 | $7.76 |
| Average True Range (ATR) | 0.24 | 0.24 |
| MACD | 0.03 | 0.09 |
| Stochastic Oscillator | 73.60 | 60.34 |
Eaton Vance Enhanced Equity Income Fund II is a diversified, closed-end management investment company. The fund's primary investment objective is to provide current income, with a secondary objective of capital appreciation. Under normal market conditions, the Fund invests at least 80% of its total assets in common stocks. It invests in a portfolio of large and mid-cap securities in sectors such as Information Technology, Consumer Discretionary, Communication Services, Healthcare, Industrials, Consumer Staples, Financials, Materials, and Energy.
Novavax Inc is a biotechnology company that develops vaccines. The company works in the clinical stage of development with a focus on delivering novel products that prevent a broad range of diseases. It works together with its wholly owned Swedish subsidiary to produce vaccine candidates to respond to both known and emerging disease threats. The company believes its vaccine technology has the potential to be applied broadly to a wide variety of human infectious diseases. The company manages its business as one operating segment, the development and commercialization of vaccines. The company generates maximum revenue from the United States.